Histopathology providers merge to serve biopharma, CRO industry as single company backed by PE

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/anyaivanova)
(Image: Getty/anyaivanova)

Related tags: Histopathology, Pathology, Private equity, Preclinical contract research

Histo-Scientific Research Laboratories and Vet Path Services have merged to create one company dedicated to providing histology, pathology, and archiving services to the biopharmaceutical, medical device, and contract research industries.

The companies will become one to meet an increasing demand for histopathology services in the research and preclinical therapeutics markets.

“The owners of the two companies saw an opportunity to expand value to clients, especially for histology and pathology services, as a single combined entity,”​ HSRL CEO Tom Galati told us.

Histo-Scientific Research Laboratories (HSRL) service offering includes tissue analyses, efficacy determination for new compounds and devices, toxicologic evaluation, and pathology reporting for good laboratory practices (GLP) studies. 

Vet Path Services’ (VPS) GLP-compliant archival offering includes cold (5°C and -20°C) and ultra-low-temperature (-80°C) material storage, among other histology and pathology services.

The combined company has offices in Mt. Jackson, VA, Mason, OH, and Worcester, MA – and has plans to “significantly”​ expand its Worcester site.

Following the merger, the middle market private equity (PE) firm Ampersand Capital Partners also has invested in the company.

“Ampersand seeks out, and invests in the top players in their respective industry segments. We target companies that have a differentiated approach and operate in high growth markets,”​ said David Anderson, PhD, partner, Ampersand Capital Partners.

Anderson told us, “Both HSRL and VPS meet these criteria and together create a formidable company to service the pre-clinical histopathology market.”

Amersand’s investment follows several​ in the industry. Most recently, the PE firm in November acquired Pacific Biomarkers​ with plans to merge the CRO with Neomed-Labs, which it bought in September​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars